Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.